ShiraTronics is a medical device company located in Minneapolis. They are developing a migraine-specific device which is placed beneath the skin and is designed to provide continuous stimulation to targeted nerves associated with migraine, potentially relieving, interrupting and preventing chronic migraine symptoms.
Ryme Medical is a medtech company based in California developing a catheter-based therapy that seeks to reduce symptoms and improve long-term outcomes in patients with Chronic Obstructive Pulmonary Disease (COPD), a debilitating condition in which chronic inflammation of the lung airways leads to difficulty breathing. Ryme Medical is addressing the critical and unmet need of COPD which affect over 320 million people globally and ranks as the third-leading cause of death worldwide.
Loci Orthopaedics is a concurrent spin-out from the University of Galway (Ireland), University College Cork (Ireland) and KU Leuven (Belgium). The company develops orthopaedic technologies to meet major unmet clinical needs with a primary focus on the orthopaedics extremities market, such as the thumb joint. The company focuses on evidence-based design to ensure that its technologies are physiologically optimal to restore natural movement for superior clinical outcomes.
Vico Therapeutics B.V. is a clinical-stage genetic medicines company developing antisense oligonucleotide (ASO) RNA modulating therapies for patients with severe neurological diseases. Vico’s research platform designs fit-for-purpose ASOs by applying precision chemistry with mechanisms of action ideally suited to target devastating neurodegenerative diseases such as Huntington’s disease for which there are currently no disease-modifying treatments available.
Based in Germany, Complement Therapeutics is a cell & gene therapy company focused on addressing unmet needs in complement (important part of the immune system) mediated diseases. The lead asset is an AAV-2 gene therapy focused on blocking the lesions in dry age-related macular degeneration (dAMD). These lesions are a major cause of vision loss in patients. The company is also exploring some earlier-stage programs.
Sibylla Biotech is based in Milan, Italy and develops a computational modelling platform to discover new protein degraders.Through their protein folding simulation technology platform, Sibylla identifies relevant and previously inexplorable folding intermediates for protein targets that are currently considered undruggable in their native state. The company is developing a proprietary pipeline of small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas.
Perfuze is based in Galway, Ireland. It develops innovative catheter technology to treat acute ischemic stroke, providing superior clinical outcomes in shorter procedural times. Perfuze has developed super-bore diameter aspiration technology that has the capability to navigate the complex neurovascular anatomy. Perfuze’ pipeline of products are designed to facilitate fast, complete clot removal during acute ischemic stroke.
Coave Therapeutics is a French based clinical-stage biotech company focused on developing life-changing gene therapies in rare ocular and CNS (Central Nervous System) diseases.Coave’s next-generation AAV-Ligand Conjugate (‘ALIGATER’) platform enables targeted delivery and enhanced gene transduction to improve the effectiveness of advanced gene therapies for rare diseases.
Atlantic Therapeutics is a spin-out from BMR (Galway). It developed a non-invasive neuromuscular electrical stimulation device to treat various forms of incontinence (stress-urinary, faecal, and mixed-urinary). Caldera Medical acquired the company’s assets in September 2023.
Prexton is a biotech focused on developing novel treatments for the debilitating symptoms of late-stage Parkinson’s disease. The company was acquired by Lundbeck in March 2018.
Apica Cardiovascular was a developer of a platform access and closure device for the delivery of therapeutic medical devices through the apex of the heart. Apica was acquired by Thoratec in July 2014.
PQ Bypass is a medical device company working to transform the treatment of long-segment femoropopliteal disease with minimally-invasive endovascular solutions. The company was sold to Endologix in April 2021.
Veryan developed innovative stent solutions to treat peripheral vascular disease. Veryan’s BioMimics 3D Vascular Stent System has a unique 3D helical geometry to improve treatment outcomes in peripheral vascular disease. The Product is FDA approved and marketed in the US.The company was acquired by Otsuka Medical in December 2018.
Novate developed a novel inferior vena cava filter that converts from a filter to a stent, providing protection to patients at risk of pulmonary embolism.The company was sold to BTG in September 2018.
Xention is a cardiovascular biotech company, specialised in the discovery and development of ion channel-modulating drugs. Its assets have now been partnered with or acquired by pharmaceutical partners.
Covagen was a biotech company that developed a novel platform technology for the discovery and development of bispecific antibodies. The company was acquired by Janssen in 2014.
Agi Therapeutics was a specialty pharmaceutical company that was focused on the development and commercialisation of specialty drug products.
The company completed an IPO in 2006 and was subsequently acquired by Vidara Therapeutics.
